Following a full submission
AWMSG advice |
||
| Status: Not recommended | ||
Teriparatide (Forsteo®) is not recommended for use within NHS Wales for the treatment of osteoporosis in men at increased risk of fracture. Teriparatide is being considered for suitability for AWMSG reassessment by the AWMSG Scrutiny Panel at their meeting on 06/02/2025. |
||
|
||
Medicine details |
||
| Medicine name | teriparatide (Forsteo®) | |
| Formulation | 20 micrograms/80 microlitres solution for injection | |
| Reference number | 306 | |
| Indication | Treatment of osteoporosis in men at increased risk of fracture |
|
| Company | Eli Lilly & Co Ltd | |
| BNF chapter | Endocrine system | |
| Submission type | Full | |
| Status | Not recommended | |
| Advice number | 2108 | |
| Scrutiny Panel meeting date | 06/02/2025 | |
| NMG meeting date | 17/09/2008 | |
| AWMSG meeting date | 15/10/2008 | |
| Ratification by Welsh Government | 18/11/2008 | |
| Date of issue | 25/11/2008 | |
| Further information Teriparatide is being considered for suitability for AWMSG reassessment by the AWMSG Scrutiny Panel at their meeting on 06/02/2025. |
||